Pioneering live biotherapeutics
in the respiratory tract.
From Systems to Synthetic Biology:
quantitative understandig for rational engineering
Building on over 10 years of research funded with over 14m € by Spanish and EU grant agencies (details here), we have developed a proprietary microbial engineering and synthetic biology toolbox that underpins a novel live biotherapeutics platform.
A novel live biotherapeutic platform for treating human lung diseases
Our platform is based on attenuated lung bacteria able to expose antigens or deliver therapeutic agents in the lung in a controlled, local and continuous manner. It allows engineering of multiple genetic circuits to specifically target and deliver payloads.
Lung Cancer
Infectious diseases
Chronic obstructive
pulmonary disease
Infectious diseases
Cystic Fibrosis
Infectious diseases
Asthma
Lung Cancer
Pulmobiotics | Platform | Respiratory diseases | Partners | Team | Contact
Academic project funding
(awarded to CRG or to consortia participated by CRG)
ERC Proof of Concept grant 335010 “Mico pLung” (2014): 150,000€
ERC grant 670216 “MycoChassis” (2015): 2,454,522€
EU Horizon 2020 grant 634942 “MycoSynVac” (2015): 8,000,000€
EraSynBio “MiniCell” (2015): 200,000€
Miguel Servet ISCIII (2017): 121,500€
EU Horizon 2020 grant 820699 “BioRoboost” (2018): 1,998,787,50€
ERC Proof of Concept grant 825566 “MycoVAP” (2018): 150,000€
La Caixa Health “MycoVAP” (2019): 999,528€